Kahles, Andy
Goldschmid, Hannah
Volckmar, Anna-Lena
Ploeger, Carolin
Kazdal, Daniel
Penzel, Roland
Budczies, Jan
Flechtenmacher, Christa
Gassner, Ulrich M.
Brüggemann, Monika
Vogeser, Michael
Schirmacher, Peter
Stenzinger, Albrecht
Funding for this research was provided by:
Universitätsklinikum Heidelberg
Article History
Accepted: 17 October 2023
First Online: 4 December 2023
Declarations
:
: A.-L. Volckmar: personal fees from AstraZeneca outside the submitted work. D. Kazdal: personal fees from AstraZeneca, Bristol-Myers Squibb, Pfizer, Lilly, Agilent and Takeda outside the submitted work. A. Stenzinger: advisory board/speaker: AGCT, Aignostics, Astra Zeneca, Bayer, BMS, Eli Lilly, Illumina, Incyte, Janssen, MSD, Novartis, Pfizer, Roche, Seattle Genetics, Takeda, Thermo Fisher; grants: Bayer, BMS, Chugai, Incyte. A. Kahles, H. Goldschmid, C. Ploeger, R. Penzel, J. Budczies, C. Flechtenmacher, U.M. Gassner, M. Brüggemann, M. Vogeser and P. Schirmacher declare that they have no competing interests.
: For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.
: The supplement containing this article is not sponsored by industry.